DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vestipitant
Vestipitant
Use and Cardiovascular Safety of Transdermal and Other Granisetron Preparations in Cancer Management
In February 2013, Glaxosmithkline (GSK) Announced a Commitment To
( 12 ) United States Patent
CDR Clinical Review Report for Akynzeo
(12) United States Patent (10) Patent No.: US 9.446,029 B2 Boscan Et Al
Use and Cardiovascular Safety of Transdermal and Other Granisetron Preparations in Cancer Management
Management of Chemotherapy-Induced Nausea and Vomiting
Guideline for the Prevention of Acute Nausea and Vomiting Due to Antineoplastic Medication in Pediatric Cancer Patients
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0231688 A1
Gsk-101287-Synopsis-Redact
Neurokinin-1 Receptor Antagonists in Preventing Postoperative Nausea and Vomiting a Systematic Review and Meta-Analysis
Neurokinin1 Antagonists Potentiate Antidepressant Properties Of
Tachykinin Receptors (Version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
Viewed in Ref
Our Tinnitus Patients Want a Drug?
REVIEW NEPA, a New Fixed Combination of Netupitant And
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Pharmacologic Rationale for the NK1R Antagonist, Aprepitant As Adjunctive Therapy in HIV Jeffrey S
Top View
Fourth Consensus Guidelines for the Management
NEPA, a New Fixed Combination of Netupitant and Palonosetron, Is A
Vasoactive Peptides